Amniox Medical, Inc. (Amniox), a TissueTech, Inc. company and pioneer in the clinical application of human birth tissue-based products, announced today the results from a retrospective study, Intra-articular Injection of Amniotic Membrane and Umbilical Cord Particulate for the Management of Moderate to Severe Knee Osteoarthritis, published in the October 19, 2020 issue of Orthopedic Research & Reviews.
Intra-articular injection of amniotic membrane/umbilical cord particulate may reduce pain and improve function in patients with moderate to severe knee osteoarthritis, according to published results.
Amniox Medical Inc., a TissueTech Inc. company, highlighted the results of two studies presented at the recent American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting. Dr. David Garras of Midwest Orthopaedic Consultants, an assistant professor at the University of Illinois at Chicago, and Dr. Ryan Scott, of the CORE Institute in Phoenix, Ariz., presented Plantar Fasciitis Treatment with Particulate Human Amniotic Membrane. Drs. Donald Covell, Bruce Cohen, Kent Ellington, Carroll Jones, Hodges Davis, and Robert Anderson, all from OrthoCarolina Foot and Ankle Institute in Charlotte, N.C., presented The Use of Cryo-Preserved Umbilical Cord Plus Amniotic Membrane Tissue in the Resection of Tarsal Coalition.
Knee osteoarthritis (OA) is a degenerative joint disease affecting nearly 14 million individuals in the United States alone. Pathologic features include articular cartilage degradation, remodeling of subchondral bone, osteophyte formation, and synovial inflammation. Initially believed to be the result of wear and tear on the joints, the pathogenesis of OA is now known to be largely driven by a complex interplay of inflammatory mediators. This inflammation, coupled with progressive articular erosion, causes pain, progressive loss of function, and diminished quality of life. Given its high prevalence, knee OA is a leading cause of physical disability in the aging population.
Treatment of peripheral neuropathy remains a challenge. It has been shown clinically that cryopreserved human amniotic membrane (AM) and umbilical cord (UC) reduce pain, and they may serve as a beneficial treatment option for peripheral neuropathy. Here, we report findings from a single-center, retrospective review of peripheral neuropathy patients treated with AM/UC particulate.
AMNIOX Medical, Inc., a TissueTech, Inc. company, announced results from a clinical study of Cryopreserved Amniotic Membrane in lumbar microdiscectomy surgery.
The study, led by D. Greg Anderson, M.D., of Rothman Institute in Philadelphia, found that pain decreased and function increased after the use of AMNIOX Medical’s CLARIX brand of amniotic membrane. Their work, “Cryopreserved Amniotic Membrane Improves Clinical Outcomes Following Microdiscectomy,” was published in the May 2017 online issue of Clinical Spine Surgery.
Study results suggest that AMNIOX Medical's CLARIX® FLO and CLARIX® CORD 1K regenerative therapies, processed from umbilical cord and amniotic membrane utilizing CryoTek technology, improved outcomes in plantar fasciitis treatment and tarsal coalition repair.
AMNIOX Medical, Inc., a TissueTech, Inc. company, announced today the results of a study demonstrating the application of its unique cryopreserved human umbilical cord tissue for the treatment of patients with plantar fasciitis. The findings were recently presented at the American College of Foot and Ankle Surgeons in Las Vegas.
74% of patients treated with CLARIX® FLO demonstrated clinically significant improvement at 12 months, signifying its potential in delaying Total Knee Arthroplasty (TKA)
Biomaterials are often used to support the healing and regeneration of bone tissue. One of the key requirements for biomaterials/ scaffolds to be considered for bone tissue engineering is the biocompatibility and degradability of such biomaterials
Infra calcaneal heel pain is a common podiatric condition taking the form of plantar fasciitis, an acute inflammation of the plantar fascial band.
In a retrospective review of patients with plantar fasciitis, all experienced significant pain reduction after injection with this human connective tissue matrix.
Knee osteoarthritis (OA) is a degenerative joint disease that causes pain and decreased function, dramatically reducing the quality of life in those affected. The prevalence of symptomatic knee OA in the United States is estimated at 15.6 million, with advanced knee OA comprising the majority of individuals. The population with knee OA is expected to continually rise, with recent estimates projecting a nearly 40% increase in the prevalence of all forms of arthritis over the period 2005–2030.